At Ipsen, we’re dedicated to improving people’s lives and health outcomes. Our 4,500 employees around the world are committed to tackling areas of high unmet medical need to improve the quality of life of patients and caregivers.
Under the overarching theme of Focus. Together. For patients & society, Ipsen is focusing on four strategic priorities to accelerate our innovation and drive positive impact for patients, employees, shareholders and society—a strategy for the short and long term.
Among the top pharmaceutical companies in the world specializing in oncology, we address challenges posed by the most difficult-to-treat cancers.
With over 25 years of research, development and commercial experience in neuroscience, we are fully committed to improving health outcomes for patients suffering from debilitating neurological disorders.
We are committed to developing innovative solutions for people living with rare diseases. By focusing our efforts on these rare conditions, we make substantial impact in areas with significant unmet needs.
Our medicines are registered in more than 100 countries worldwide and we have a direct commercial presence in over 30 countries.
Founded 1929, Ipsen has been a family-owned business for the past 90 years and is a publicly traded business. We have four global R&D hubs and four pharmaceutical development centers around the world, and we invested €428.4m in R&D in 2021 alone.
In 2021, total sales exceeded €2.8bn, with a growth of 10.5% in North America.
We are one of the world’s top 15 biopharmaceutical companies in terms of oncology sales.
* members of the Executive Leadership Team
Chief Executive Officer
David Loew was appointed as Chief Executive Officer of Ipsen on July 1, 2020.
David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region. In 2016, David was appointed CEO of Sanofi Pasteur Vaccines.
David currently serves on the Boards of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and G5 Santé, the federation of French pharmaceutical companies.
David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland.
Executive Vice President,
Strategy, Transformation and Digital
Catherine Abi-Habib joined Ipsen in 2022
as Executive Vice President, Strategy, Transformation and Digital.
Prior to joining Ipsen, Catherine spent more than 10 years working with pharmaceutical and biotech companies, health systems, payors, providers, and charitable foundations. She joined Ipsen from McKinsey, where she was a Partner in the Life Sciences practice based in London. Working closely with QuantumBlack, McKinsey’s advanced analytics firm, she partnered with leading biopharma companies on large-scale digital and analytics driven transformations
across North America, Europe and Asia, focused on improving physician experience.
Catherine holds an MSc. in Economics from the London School of Economics and a BA in Mathematics from the University of Cambridge, Trinity College.
Bartosz (Bartek) Bednarz*
Executive Vice President,
Head of Global Product and Portfolio Strategy
Bartosz (Bartek) Bednarz, DDS joined Ipsen in 2017.
He currently serves as Executive Vice President, Head of Global Product and Portfolio Strategy at Ipsen, which covers Global Franchises, Global Value and Access and Global Strategic Business Excellence.
Before assuming his current role, Bartosz successfully led Ipsen’s oncology franchise. Prior to that, he held global leadership roles at AstraZeneca and Novartis. At AstraZeneca, where Bartosz spent seven years, he started as Country President and later led new launches in oncology as well as Oncology Commercial Operations at a global level while based in Cambridge (UK). At Novartis, Bartosz held various commercial leadership roles at local, regional and international levels around the world, including Poland, Spain, Switzerland and Canada. He has worked across multiple therapeutic areas and is very passionate about Ipsen’s focus in oncology, rare disease and neuroscience.
Bartosz Bednarz holds a Doctor of Dental Medicine, and he obtained his diploma with honors at the Medical University of Pomerania in Poland.
Executive Vice President,
President of North America
Stewart Campbell was appointed Executive Vice President and President of North America in November 2021.
Stewart joined Ipsen as Senior Vice President and Franchise Head of Oncology in May 2021 from Roche/Genentech where he spent more than 14 years, responsible for the lifecycle management of some of Roche’s oncology blockbusters, including both commercial and clinical development globally. Through a career of more than 20 years in the pharmaceutical industry, Stewart has deep experience leading country and global commercial functions in oncology and specialty care markets, including Canada, Switzerland, and the United States.
Stewart is a graduate of Concordia University in Montreal, Canada, where he received his B.S. in physiology with a minor in physics. He received his MBA in corporate finance from Queens University in Kingston, Canada and an additional MBA in business strategy from the Johnson School of Management at Cornell University in Ithaca, New York.
Executive Vice President,
General Counsel and Chief Business Ethics Officer
François Garnier was appointed Executive Vice President, General Counsel in December 2014.
François began his career in 1989 at Servier S.A. as International Contracts Manager and remained with the company until September 1995. He then moved to Rhône Poulenc Rorer S.A. to take up the position of Counsel for Corporate Transactions. In 1996 he moved to the United States as Associate Counsel, before being appointed Chief Counsel for France in 1999. François continued his career as Chief Counsel at Aventis Animal Nutrition until 2001, when he joined the Pharmacia Group as Chief Counsel for Europe.
François joined Pfizer France in 2003, as Vice-President, General Counsel before moving on to become Chief Counsel for Pfizer’s operations in Europe from 2009 to 2014. He was International Chief Counsel (ex-US) for Pfizer Inc. from January 2014.
A student from the IEP in Paris, Francois graduated from the University of Panthéon-Assas.
Steven Hildemann*, M.D., Ph.D.
Executive Vice President,
Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients Affairs
Steven Hildemann, M.D., Ph.D. joined Ipsen in March 2020 as Chief Medical Officer.
Prior to joining Ipsen, Steven held leadership roles in science-based bioethics and built an innovative digital health startup in cancer care after serving for five years as Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs and Global Patient Safety at Merck. He also held several strategic leadership positions with biopharmaceutical companies such as Pharmacia-Pfizer and Schering-Plough-MSD.
Steven is board certified in internal medicine and cardiology with broad clinical training across internal medicine including medical oncology, gastroenterology, rheumatology and pulmonary oncology at university hospitals in Munich, Germany. Throughout his career, he has engaged in part-time clinical practice, late-stage pharmaceutical research and medical teaching. Steven received his M.D., Ph.D. at the Albert Ludwig University of Freiburg, Germany, where he continues to serve as an adjunct Professor of Medicine.
Aymeric Le Chatelier*
Executive Vice President,
Group Chief Financial Officer
Aymeric Le Chatelier was appointed Executive Vice President, Group Chief Financial Officer in November 2014.
Aymeric, a graduate from HEC Business School, started his career at Arthur Andersen. He successively executed several roles in finance in France and the United States at Veolia. He then joined Arjowiggins, a leading manufacturer of creative and technical paper, as Group Chief Financial Officer. He was subsequently appointed Financial Director of Enedis and member of the Management Board.
Aymeric served as interim Chief Executive Officer of the Group from 1 January 2020 until David Loew was appointed Chief Executive Officer in July 2020.
Executive Vice President,
Chief Business Officer
Philippe Lopes-Fernandes joined Ipsen in October 2020 as Executive Vice President, Chief Business Officer.
With more than 20 years of leadership and expertise in global business development and acquisitions within the pharmaceutical industry, Philippe is responsible for driving Ipsen’s external innovation strategy and strengthening alliances across its key therapeutic areas of oncology, neuroscience and rare disease. He has an extensive track record of creating successful business development deals in multiple therapeutic areas in Europe, Asia and North America.
Prior to joining Ipsen, Philippe worked at Merck KGaA where he was the Senior Vice President, Global Head of Business Development and Alliance Management. Before that, he held a variety of roles at Merck KGaA in Business Development, Mergers & Acquisitions, Finance and Marketing in Germany, France, Portugal, Switzerland and the United States.
Philippe received his degree from the Institut Supérieur de Gestion (ISG) in Paris in 1994. He is a French External Trade advisor (Conseiller du Commerce Extérieur) and board member of several companies.
Howard Mayer*, M.D
Executive Vice President,
Head of Research and Development.
Howard Mayer, M.D. joined Ipsen in December 2019 as Executive Vice President, Head of Research and Development.
Howard joined Ipsen from Shire, where he was Chief Medical Officer, responsible for the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas.
Previously, he served as Chief Medical Officer at EMD Serono, a division of Merck KGaA. Prior to that, he held a variety of global roles at Pfizer, including Head, Clinical Development and Medical Affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as Director of Clinical Research at Bristol-Myers Squibb.
Howard obtained his B.A. from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the board of directors for Genocea Biosciences and Entasis Therapeutics, and on the board of Autism Speaks in New England. He was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry in both 2011 and 2017.
Executive Vice President,
Chief Human Resources Officer
Régis Mulot joined Ipsen in March 2018 as Executive Vice President, Chief Human Resources Officer.
Prior to joining Ipsen, Régis served as Executive Vice President, Chief Human Resources Officer at Staples Inc., the global specialty retail and e-commerce company and led a global team of over 600 professionals. Prior to his career with Staples (2009-18), Régis held HR leadership positions with Levi Strauss & Co (2002-08) and the technology start-up Broadnet Europe (2000-02), following earlier roles at GTECH Corporation (1994-2000), International Post Corporation (1991-94) and Chronopost SA (1989-91).
Régis served on the Board of Trustees, Simmons College (Boston, MA, USA); is Past Chairman of the Business Advisory Committee of the Simmons School of Management 2014-2017; Founder and former chair of the French-American HR Forum since 2016-2018. He has been co-chair of the Boston CHRO (Chief Human Resources Officers) Leadership summit between 2014 and 2018 and is a Gartner CHRO Leadership Board member since 2017.
Régis holds a DESS Entreprises Publiques (Master in Public Administration) from Paris XI-Sud in partnership with Paris IX-Dauphine and Institut International d’Administration Publique (IIAP). He also holds a Maîtrise Droit Public (Bachelor of Law) from Paris II–Panthéon-Assas and is a Beta Gamma Sigma honoree from the Simmons College Chapter.
Aidan Murphy*, Ph.D.
Executive Vice President,
Aidan Murphy, Ph.D. was appointed Executive Vice President, Technical Operations in January 2018.
Aidan has more than 25 years’ experience in the pharmaceutical and biotechnology industry, and since joining Ipsen in 2006 has held several manufacturing leadership roles across the globe.
Prior to his current role, Aidan was Senior Vice President, Biologics Development and Manufacturing, and has also led Ipsen’s manufacturing sites in Tianjin (China), Dublin (Ireland), and Wrexham (UK) and occupied global roles as SVP CMC (Chemistry, Manufacturing, and Controls) Development & Engineering and Head of Specialty Care Manufacturing. He holds a Ph.D. in organic chemistry from Trinity College, Dublin.
Executive Vice President,
Specialty Care International
Mari Scheiffele joined Ipsen in November 2021 as EVP and President, Specialty Care International.
Mari brings 20 years of healthcare leadership experience, from across the pharmaceutical industry, having worked in the US, Europe and in Japan. She joined Ipsen from Novartis where she had held both global strategy and country operational roles in Japan and in the UK. Prior to joining Ipsen, Mari was the General Manager, Novartis Oncology UK & Ireland where with a focus on patient-centricity, evidence-based medicine, and partnership, she drove a successful business transformation.
In addition to her focus in oncology, Mari has worked in other specialty care environments such as ophthalmology, neuroscience, and immunology. Prior to Novartis, Mari was a partner at McKinsey & Company in New York and in Switzerland in pharmaceuticals and medical products.
Mari holds a doctorate in neuroscience from Harvard Medical School.
Executive Vice President,
Communications and Public Affairs
Gwenan White joined Ipsen on March 1, 2021 as Executive Vice President, Communications and Public Affairs.
In her role, Gwenan is responsible for designing, implementing and managing the communications and public affairs strategy for Ipsen. She brings 30 years of experience in pharmaceuticals at global, regional and country roles. Before joining Ipsen, Gwenan was the Global Head of Pharma Communications and Patient Advocacy at Novartis and member of the Pharma Executive Committee. Over the course of her career, she has held a variety of leadership roles of in public affairs, corporate, science and product communications, patient advocacy and marketing at AbbVie, GSK and Schering-Plough.
Gwenan holds a degree in Biochemistry from the University of Liverpool.
Board of Directors
The Board of Directors ensures that the company’s shareholders and the general public are provided with accurate information. It ensures that the company has reliable procedures for identifying, measuring and monitoring its commitments and risks, as well as adequate financial and operational internal controls.
Chairman of the Board of Directors
Marc de Garidel
Marc de Garidel – Chairman of the Board of Directors
Marc de Garidel joined Ipsen as Chairman and Chief Executive Officer in November 2010. He has been the Ipsen Chairman of the Board of Directors since July 2016.
Marc de Garidel is also Chief Executive Officer and Director of AZTherapies, Inc. since October 1st, 2020. He was previously, for 2 years and a half, Chief Executive Officer and Director of Corvidia Therapeutics, Inc. which was sold to Novo Nordisk in July 2020.
Marc de Garidel started his career with the group Eli Lilly and pursued at Amgen, from 1995 to 2010, with increasing responsibility positions in the US and Europe.
Marc de Garidel is Director of Claris Biotherapeutics since July 2020.
Previously, he was Director of several biotechnology companies, including Vice-Chairman of the Board of Directors of Vifor Pharma (Switzerland) between May 2017 and 2018 (formerly Galenica), of which he was member of the Board since 2015.
Marc de Garidel is a graduate from the French Engineering School ESTP and has an Executive MBA from Harvard Business School.
The Board of Directors has set up six permanent committees and has defined both the composition and powers of these committees.
Ipsen divests from its CHC business
July 2022: Ipsen announces the closing of its agreement to divest its CHC business to Mayoly Splinder
Ipsen Strengthens Early Stage Pipeline in Neuroscience and Oncology
August 2021: Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders.
July 2021: Ipsen strengthens its pre-clinical oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway.
July 2021: Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease.
Ipsen Announces New Strategic Priorities
December 2020: Ipsen announces new strategic priorities with the aim of driving continued growth and bringing transformative medicines to patients.
May 2020: Ipsen and IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, entered into an option agreement by which Ipsen acquires an exclusive license for the worldwide rights to a high-value oncology program.
Acquisition of Clementia Pharmaceuticals
Ipsen and Clementia Pharmaceuticals announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court.
Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist.
Acquisition of oncology assets from Merrimack pharmaceuticals
Ipsen announced that it has entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE® (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin.
Ipsen’s oncology pipeline reinforced by a licensing deal with Exelixis
Exelixis, Inc. and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug. Under the agreement, Ipsen has exclusive commercialization rights for current and potential future cabozantinib indications outside the United States, Canada and Japan, including COMETRIQ® (cabozantinib).
Ipsen opened its new peptide-driven R&D center in Cambridge, MA (USA)
- April: Ipsen opened its peptide-driven R&D center in Cambridge (USA).
- May: Ipsen strengthened its oncology expertise with the acquisition of OctreoPharm Sciences, a German company developing innovative radiopharmaceutical products for the diagnosis and treatment of neuroendocrine tumors.
- July: The U.S. Food and Drug Administration approved DYSPORT® (abobotulinumtoxinA) as a treatment for adult upper-limb spasticity in the US.
- Ipsen strengthened its consumer healthcare portfolio with the launch in France of strawberry-flavored SMECTA® and SMECTALIA® stick for adults, an OTC ready-to-use formulation of SMECTA®.
Ipsen’s SOMATULINE® DEPOT® (lanreotide) Injection gets U.S. FDA approval
- SOMATULINE® DEPOT® (lanreotide) Injection 120 mg (referred to as SOMATULINE®) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences. The 2011-2014 collaboration enabled significant steps forward in the understanding of basic biological mechanisms.
- The Fondation Ipsen celebrated its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer,” attended by 8 Nobel Prize laureates and scientists in biomedical research.
Teijin Pharma Limited and Ipsen launched SOMATULINE® (lanreotide) in Japan
- Teijin Pharma Limited and Ipsen launch of SOMATULINE® (lanreotide) 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism.
- Ipsen and Inspiration Biopharmaceuticals announce closing of the sale of OBI-1 and Milford facility to Baxter International
- Health Canada granted marketing authorization for DYSPORT® (abobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market DYSPORT® for use in aesthetic medicine in Canada.
- Ipsen strengthens its neuroscience R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology.
SOMATULINE® (lanreotide) receives marketing authorization in Japan
- SOMATULINE® (lanreotide) receives marketing authorization in Japan for the treatment of acromegaly and pituitary gigantism and becomes Ipsen’s first drug available worldwide.
- Ipsen enters into a research partnership with Oncodesign to develop new therapeutic agents
Ipsen announces a new development strategy based on three pillars
Ipsen announces a new development strategy based on three pillars:
- Focus resources and investments on specialty care
- Invest to grow through the development of new compounds and product life-cycle management programs
- Leverage the full potential of the Group’s geographical footprint
Ipsen and the Salk Institute renew the “Ipsen Life Sciences Program” for a further three years.
Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics.
Ipsen strengthens its business in urology-oncology with the acquisition of the rights to HEAVY® (a drug aimed at improving bladder cancer detection) and the establishment of two significant partnerships with: Active Biotech for the co-development and commercialization of tasquinimod (a molecule for the treatment of metastatic and castration-resistant prostate cancers), and Institut Gustave Roussy in the area of medical oncology to leverage the combined expertise of their respective R&D teams.
Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership
- Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership to create a hemophilia franchise.
- Ipsen increases its presence in oncology and endocrinology in South-East Asia through a commercialization agreement with Invida.
- Ipsen grants Menarini exclusive license rights to ADENURIC® (for the treatment of chronic hyperuricemia in gout) in 41 countries.
- Ipsen and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, enter into a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.
- Ipsen grants Rhythm an exclusive worldwide license for research, development, and commercialization of its melanocortin and ghrelin programs originating from Ipsen’s research.
Ipsen and Galderma receive green light for AZZALURE® (botulinum toxin type A)
- Ipsen and Galderma receive collective green light for AZZALURE® from 15 European countries’ Health Authorities for the granting of national marketing authorizations for the treatment of glabellar lines.
- AZZALURE® receives marketing authorization in the UK, France and Germany. The FDA approves DYSPORT® (abobotulinumtoxinA) for therapeutic and aesthetic use.
- The European Medicines Agency (EMA) delivers marketing authorization for the 6-month formulation of DECAPEPTYL® (triptorelin pamoate) in nine European countries. The product is launched in France.
Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego)
- Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego, US) aimed at improving understanding of proliferative and degenerative diseases.
- Ipsen reinforces its presence in the US with three acquisitions: Tercica Inc. in endocrinology, APOKN® in neurology and Vernalis’ US commercial operations, and all assets related to OBI-1 from Octagen in hematology.
Ipsen enters into a partnership with Galderma
- The Group enters into a partnership with Galderma, for the development, promotion and distribution of the Group’s botulinum toxin type A in aesthetic medicine indications.
- SOMATULINE® DEPOT (lanreotide) obtains marketing authorization in the United States for the treatment of acromegaly. SOMATULINE® DEPOT is the first product stemming from Ipsen’s R&D to be approved by the FDA.
- Ipsen’s shares are admitted to the SBF 120 index in France.
Ipsen enters into an agreement with Medicis (now Valeant)
- Ipsen enters into an agreement with Medicis (now Valeant) to market its botulinum toxin in aesthetic medicine indications in the US, Canada and Japan.
- Ipsen and Tercica complete worldwide strategic collaboration agreement in Endocrinology. Ipsen grants Tercica exclusive rights to market SOMATULINE® AUTOGEL® (lanreotide) in the United States and in Canada.
- Tercica grants Ipsen exclusive rights to market INCRELEX™ (mecasermin), a leading product in the United States for the treatment of short stature associated with severe primary IGF-1 deficiency in all territories excluding the United States, Japan, Canada, Taiwan and certain countries of the Middle East and North Africa.
Ipsen’s shares are listed on Euronext Paris.
- Ipsen’s shares are listed on Euronext Paris.
- Ipsen enters into a licensing agreement with Radius through which Radius acquires the exclusive worldwide rights (excluding Japan) to develop, manufacture and distribute Ipsen’s osteoporosis proprietary molecule.
The Group opens a botulinum toxin manufacturing facility in Wrexham, UK
- The Group opens a botulinum toxin manufacturing facility in Wrexham, UK.
Ipsen and Teijin enter into an agreement to develop and market four Ipsen products
- Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably SOMATULINE® AUTOGEL® (lanreotide), in Japan and a Teijin product for the treatment of gout in Europe.
Ipsen launches SOMATULINE® AUTOGEL® (lanreotide) in multiple countries
- Ipsen launches SOMATULINE®AUTOGEL® (lanreotide) in the UK, France followed by many other countries, strengthening Ipsen’s competitive position.
The Group opens a manufacturing facility in China
- The Group opens a manufacturing facility in China to produce SMECTA® for the Chinese market, a treatment of reference in the country.
Ipsen launches FORLAX®
Ipsen launches FORLAX®, a product used for the treatment of constipation.
The Group launches SOMATULINE® (lanreotide), a sustained-release peptide
- The Group launches SOMATULINE® (lanreotide), its sustained-release peptide for the treatment of acromegaly and neuroendocrine tumors in France.
Ipsen acquires Speywood, the company that developed DYSPORT® (abobotulinumtoxinA)
- Ipsen acquires Speywood, the company that developed DYSPORT® (abobotulinumtoxinA) for the treatment of movement disorders and various forms of muscular spasticity.
- Ipsen establishes a sales platform for its biological product and opens an office in Russia.
Ipsen begins its development in China
- Ipsen begins its development in China, with the opening of a representative office in Tianjin.
The Group creates La Fondation Ipsen under the aegis of the Fondation de France
The Group creates La Fondation Ipsen under the aegis of the Fondation de France. Its mission is to foster interactions between leading scientists in the field of life sciences.
Ipsen initiates a partnership with Debiopharm
- Ipsen initiates a partnership with Debiopharm. This collaboration leads to the marketing of DECAPEPTYL® (triptorelin pamoate) in 1986. This analogue of natural GnRH hormone (or gonadotropin) is indicated for the treatment of prostate cancer, endometriosis and infertility. DECAPEPTYL® has been a key driver of the Group’s international expansion.
The Group enters an expansion phase
- The Group enters an expansion phase with the launch of GINKOR®, TANAKAN® and SMECTA®. The Group creates Laboratoires Ipsen (Institute of Synthetic Products from Natural Extraction).
The Group opens its first research facility in Les Ulis (France)
- The Group opens its first research facility in Les Ulis (France).
The Group launches Citrate de BETAïNE®
- The Group launches Citrate de BETAïNE®, a product used in the symptomatic treatment of dyspepsia.
Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France)
- Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France) to launch ROMARÉNE®, a product derived from rosemary for the treatment of digestive disorders.